Pilot Study: KeraStat(R) Cream for Radiation Dermatitis
Phase: NA
Conditions: Radiation Dermatitis
Sponsor: KeraNetics, LLC

Kerarc>Netics 
STUDY DEVICE: KeraStat Cream 
STUDY NUMBER: KSCM-CRD-001 
VERSION: 0 
EFFECTIVE DATE: 3-1-2018 
PILOT STUDY: KERASTAT™ CREAM FOR 
RADIATION DERMATITIS 
KeraNetics, LLC. 
DN: PRO-KSCM-CRD-001(01) 
Sponsor: KeraNetics, LLC 
200 East 1st Street, Suite 102 
Winston-Salem, North Carolina 27101 
USA 
Tel: 336 725 0621 
Fax: 336 725 0619 
CONFIDENTIAL 
Page 1 

Kerarc>Netics 
Study: *-SCM CRD OOz 
Version: 00 
CW J.3Mor I'? 
Effective Date: 
2 (H 2018 3- 1- JOIS 
KERANETICS SIGNATURE PAGE 
Approver(s): 
Luke Burnett, Ph.D. 
Chief Science Officer 
KeraNetics, LLC. 
DN: PRO-KSCM-CRD-001(01) 
Date: 
CONFIDENTIAL 
Page2 

Kerarc>Netics 
Study: KSCM-CRD-001 
Version: 00 
Effective Date: 
02 01 201s3-1-Jot? 
KERANETICS CLINICAL STUDY PROTOCOL 
KeraStat® Cream for Radiation Dermatitis 
Study Number: KSCM-CRD-001 
CONTACT INFORMATION 
Sponsor Contact: 
Alexis Gabard 
KeraNetics, LLC 
Investigator Site Network: 
200 East 1st Street, Suite 102 
Winston-Salem, North Carolina 27101 
USA 
Tel: 336-725-0621 
Fax: 336-725-0619 
Email alexis.gabard @keranetics .com 
Principal Investigator: 
Karen M. Winkfield, MD, PhD 
Wake Forest Baptist Comprehensive Cancer Center 
1 Medical Center Blvd 
Winston-Salem, NC 27157 
This study will be conducted according to the protocol and in compliance with Good Clinical 
Practice (GCP) and other applicable regulatory requirements. 
KeraNetics, LLC. 
CONFIDENTIAL 
Page 3 
DN: PRO-KSCM-CRD-001(01) 

Kera@N
etic s 
Study: KSCM-CRD-00 I 
Version: 00 
Effective Date: 
~01-?0lit 
.3- l-.:2DI~ f'i,lo/3f.1a 1'6 
INVESTIGATOR'S AGREEMENT 
I agree: 
• 
To assume responsibility for the proper conduct of the study at this site. 
• 
To conduct the study in compliance with applicable regulatory requirements, this protocol, any future 
amendments, and with any other study conduct procedures provided by KeraNetics (KN). 
• 
Not to implement any changes to the protocol without agreement from the sponsor and prior review and 
written approval from the Institutional Review Board (IRB) or Independent Ethics Committee (IEC), except 
where necessary to eliminate an immediate hazard to the subjects, or for administrative aspects of the study 
(where permitted by all applicable regulatory requirements). 
• 
That I am thoroughly familiar with the appropriate use of the study device(s), as described in this protocol, and 
any other information provided by the sponsor including, but not limited to, the following: the current 
directions for use/product labeling or equivalent document, and approved product label (if the product is 
marketed in this country and the label is not already provided). 
• 
That I am aware of, and will comply with, "good clinical practices" (GCP) and all applicable regulatory 
requirements. 
• 
That I will provide full and unencumbered access to source documents and medical records needed for KN, 
representatives of KN and regulatory authorities to verify source data and related documentation with respect 
to this trial. 
• 
To ensure that all persons assisting me with the study are adequately informed about the KN study device(s) 
and of their study-related duties and functions as described in the protocol. 
• 
That I have been informed that certain regulatory authorities require the Sponsor to obtain and supply, as 
necessary, details about the Investigator's ownership interest in the Sponsor or the study device, and more 
generally about his/her financial ties with the Sponsor. KN will use and disclose the infonnation solely for the 
purpose of complying with regulatory requirements. 
Hence I: 
• 
Agree to supply KN with any necessary information regarding ownership interest and financial ties (including 
those ofmy spouse and dependent children); 
• 
Agree to promptly update this information if any relevant changes occur during the course of the study and for 
1 year following completion of the study; and 
• 
Agree that KN may disclose any information it has about such ownership interests and financial ties to 
regulatory authorities. 
KeraNetics, LLC. 
oN: P~o-Ksctv1
-cen-001Lo1) 
C.t1.L;i3 Mar I g 
CONFIDENTIAL 
Page4 

Effective Date: 
Kera rc>N eti cs 
Study: KSCM-CRD-001 
Version: 00 
92 01 201-83-1-JOI~ CW«..3Har 
l<o' 
1. 
SYNOPSIS 
Name of Company: 
I Name of Product: 
I Type of Study: 
KeraNetics, LLC 
KeraStat® Cream 
Clinical Proof of Concept 
Title of Study: Pilot Study: KeraStat® Cream for Radiation Dermatitis 
Investigator(s): Karen M. Winkfield, MD, PhD; Doris Brown, MD, PhD 
Study Period: Estimated screening expected to start March 2018; Expected completion September 2018 
Phase of Development: Design & Development (Phase 3 of Design Control) 
Objective(s): 
Primary: 
• 
To assess feasibility (compliance ofuse) 
• 
Collect data for designing a larger future trial evaluating KeraStat Cream 
Secondary: 
• 
To assess the safety and tolerability ofKeraStat Cream in subjects at risk ofradiation dermatitis 
• 
To assess the effectiveness of KeraStat Cream compared to standard of care to manage the symptoms of 
radiation dermatitis in subjects being treated with radiation therapy 
• 
To estimate amount ofKeraStat Cream used per patient and coverage on skin 
Methodology: This is a randomized, open label study. 
Number of Subjects: 
Sufficient subjects will be screened and enrolled such that 24 total subjects, 12 subjects per treatment group, will 
complete the study through the Follow-Up Visit. With 12 participants in each treatment group, we will be able to 
calculate a 95% confidence interval around the compliance rate in each group with a maximum margin of error of 
0.283. Comparisons between groups for effectiveness will have 80 percent power to detect a difference of 1.2 
standard deviations. Results of the current study are intended to provide descriptive endpoint data to inform the 
design of a future clinical evaluation of product effectiveness. 
Study Overview: 
Study Periods: 
The length of study participation for a subject is about 8-12 weeks, depending on the length of radiation 
treatment. The study will extend 4-6 weeks beyond the end of radiation therapy. The study will begin with a 
Screening Visit during treatment planning followed by weekly assessments during radiation therapy, and a follow 
up visit 4-6 weeks after completion of therapy. There is a total of 5-7 visits. 
Study Assessments: 
At the Screening/Baseline Visit (Visit 1, Week 0), following informed consent, initial eligibility will be verified 
per the inclusion/exclusion criteria and demographics and brief medical history will be collected. Subjects will 
be randomized to receive standard of care or KeraStat Cream. A physical exam and photograph of the area to be 
irradiated will be obtained, and subjects will complete the De1matology Life Quality Index. 
During the course of radiation therapy (4-6 weeks) and for the duration of the post RT treatment period (4-week 
follow up), subjects will complete a daily diary detailing symptoms and treatment details. Weekly from week 2 
of RT until the end of treatment, study staff will assess the subject for radiation dermatitis by recording the 
RTOG for Radiation-Induced Acute Skin Toxicity scores and taking photographs. The same evaluation will be 
performed at the follow up visit after treatment. Subjects will complete the Dermatology Life Quality Index at 
each visit. 
Inclusion Criteria: 
Subjects must meet all of the following criteria: 
1. Age 18 to 70 
2. 
Female 
3. 
Diagnosis of early stage (stage 0-2) breast cancer and scheduled to receive 4-6 weeks of fractionated 
radiation therapy as part of breast conserving therapy following lumpectomy 
KeraNetics, LLC. 
CONFIDENTIAL 
Page 5 
DN: PRO-KSCM-CRD-001(01) 

Effective Date: 
Kerarc>Netics 
Study: KSCM-CRD-001 
Version: 00 
Q2 Ql 2Ql8 .3- hWl'8 ClJJ.3Nor 1'8 
Name of Company: 
KeraNetics, LLC 
I 
Name of Product: 
KeraStat® Cream 
I 
Type of Study: 
Clinical Proof of Concept 
Exclusion Criteria: 
To participate in the study, subjects must not meet any of the following criteria: 
1. Previous radiation therapy to the area to be treated with radiation therapy 
2. 
Receiving palliative radiation therapy 
3. Low dose radiation protocol 
4. 
Unhealed or infected surgical sites in the irradiation area 
5. 
Patients undergoing cytotoxic chemotherapy or concurrent Herceptin as part of overall treatment plan 
(tamoxifen/aromatase inhibitor allowed) 
6. 
Use of oral co1ticosteroids or topical co1ticosteroids in the i1rndiation area 
7. 
Autoimmune disease 
8. 
Skin disease in target irradiation area 
9. 
Known allergy to the standard of care or any of the ingredients in KeraStat Cream 
Test Product(s), Dose, and Mode of Administration: 
Investigational: KeraStat® Cream should be applied topically to the irradiation area and 1cm beyond the border 
of the affected area twice daily. Expel the cream from the tube. Smooth the cream over the target area to cover 
with a thin layer; do not rub the cream in. 
Control: The standard skin care product should be applied topically to the irradiation area and 1cm beyond the 
border of the affected area twice daily. Smooth the product over the target area to cover with a thin layer; do not 
rub the product in. 
Duration of Treatment: 
The length of study pmticipation for a subject is about 8-12 weeks. 
Concomitant Medication Restrictions: 
Chemotherapy, steroids 
Criteria for Evaluation: 
Effectiveness Evaluation: 
Primary 
• 
Safety and tolerability will be evaluated throughout the study utilizing patient repo1ted outcomes 
• 
Adverse events will be recorded throughout the study. 
Secondary 
• 
Maximum severity of radiation dermatitis as assessed by the RTOG Criteria for Radiation-Induced Acute 
Skin Toxicity. 
• 
Number of subjects with Grade I radiation dermatitis 
• 
Number of subjects with Grade II radiation dermatitis 
• 
Number of subjects with moist desquamation present 
• 
Change from baseline in the Dermatology Life Quality Index 
Statistical Methods: 
Feasibility: 
Feasibility will be determined based on the average number of applications per week for a participant. Participants 
who average at least 10 applications per week will be classified as compliant. A 95% confidence interval will be 
calculated for the observed compliance rate. Along with the compliance rate, the number of tubes of KeraStat 
Cream used and the estimated surface area (bra size used as a surrogate) to be covered for each participant will be 
used to evaluate the coverage. 
Safety: 
All subjects who are randomly assigned to a treatment and receive at least one application ofKeraStat Cream or 
standard of care will be included in the safety and tolerability analysis. Safety will be evaluated by examining the 
KeraNetics, LLC. 
CONFIDENTIAL 
Page6 
DN: PRO-KSCM-CRD-001(01) 

Effective Date: 
Kerarc>Netics 
Study: KSCM-CRD-001 
Version: 00 
.02 !H 2018 3 - /- ,Wl~(l..1,lJ3"'1orl8' 
Name of Company: 
KeraNetics, LLC 
I 
Name of Product: 
KeraStat® Cream 
I 
Type of Study: 
Clinical Proof of Concept 
incidence, grade, type of adverse events and changes in clinical laboratory test values, physical examination 
results, and vital signs measurements from the Screening Period through study completion. 
Effectiveness: 
Descriptive statistics will be generated to detennine any trends and to supp01t a power calculation for a large 
follow-up study. Tests comparing the two treatment groups will be done for all outcomes of effectiveness 
including, skin appearance, the Dermatology Life Quality Index score, and the RTOG skin score. Qualitative 
assessments of patient-reported skin condition and satisfaction with the intervention will be assessed for themes. 
KeraNetics, LLC. 
CONFIDENTIAL 
Page 7 
DN: PRO-KSCM-CRD-001(01) 

Effective Date: 
Ke r arc>Netics 
Study: KSCM-CRD-001 
Version: 00 
02 01 lQ18 .3+ ~O\? cw .;i3 Hor I'? 
2. 
TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF 
FIGURES 
TABLE OF CONTENTS 
1. 
SYNOP SIS ................ ......................................................... ...................................... 5 
2. 
TABL E OF CONTENTS , LIST OF T ABLES, AND LIST OF FIGURES ................ 8 
3. 
LIST OF ABBREV IATIONS AND DEFINITIONS OF TERMS ........................... 11 
4. 
INTRODUCTI ON .................................................................................................. 12 
4. 1. 
Background ...................................... ...................................................................... 12 
4.2. 
Rationa le ................................... ............................................................................. 13 
5. 
TRIAL OBJECTIVES AND PURPOS E ...................................................... ........... 13 
5.1. 
Objectives ............................... ............................... ................................................ 13 
6. 
INVESTIGATIONAL PLAN ................................................................................. 14 
6.1. 
Overa ll Study Design ........................................................ .............. ........................ 14 
6.2. 
Detailed Study Design ..................................................... ................ ....................... 15 
6.2.1. 
Identification of Subjects and Consent .................................................................... 15 
6.3. 
Number ofSub jects ................................................................................................ 15 
6.4. 
Treatn1ent Assignment ............................................................................................ 16 
6.5. 
Study Procedures ............................................................................................... ..... 16 
6.5.1. 
Visit 1 .................................................................................................................... 16 
6.5.2. 
Week ly Visits throug h Radiation Therapy .............. ........................... ..................... 16 
6.5.3. 
Post-Radiation Therapy/C lose-Out Visit .................................. ............................... 16 
6.6. 
Criteria for Study Teim ination ........................................................... ................. .... 16 
7. 
SELECTION AND WITH DRAWAL OF SUBJECTS ...................... ...................... 17 
7.1. 
Subject Inclus ion Criteria ....................................................................................... 17 
7.2. 
Subject Exclusion Criteria ......................................... ......... ......... ........... ................ 17 
7.3. 
Subject Completi on and Withdrawal.. ............................................. ........................ 18 
7.3.1. 
Subject Completion ....... ................... ................................................ ...................... 18 
7.3.2. 
Patient Withdrawa l (Premature Discontinuation from the Study) ...................... ...... 18 
7.3.3. 
Replacement of Patients ......................................................................................... 18 
8. 
TREATMENT OF SUBJECTS ....................................................... ....................... 18 
8.1. 
Description of Subj ect Device ................... .......... ................................................... 18 
KeraNetics, LLC. 
CONFIDENTIAL 
Page 8 
DN: PRO-KSCM-CRD-001(01) 

K 
@N 
t · 
Study: KSCM-CRD-001 
era 
e 
ICS 
Version: oo 
Effective Date: 
-82 01·20Ht3- hWI~ CWa.3Mor I~ 
8.2. 
8.2.1. 
8.3. 
9. 
9.1. 
9.2. 
9.3. 
9.4. 
9.5. 
9.6. 
9.7. 
10. 
10.1. 
10.2. 
11. 
11.1. 
11.2. 
11.3. 
11.4. 
11.5. 
11.5.1. 
11.5.1.1. 
11.5.1.2 . 
11.5.2. 
11.6. 
11.6.1. 
11.7. 
11.7.1. 
11.7.2. 
11.8. 
11.8.1. 
11.8.1.1. 
Concomitant Medications and Therapies ............................. ............. ...................... 19 
Pharmacolo gical Therapy ..................... ....................... ...... ..................................... 
19 
Randomization ............... ............. ........................................................................... 
19 
STUDY DEVICE MATERIALS AND MANAGEMENT .................. .................... 19 
Study Device ................. ................. ........ ...........................................
................. .... 19 
Study Device Packaging and Labeling ......... ........... ................ .................. .............. 19 
Study Device Storage ........... ............ .....................................
.............. ........... ........ 19 
Study Device Preparation ...............................................
...... ............. ..................... 19 
Administration ............. ......................................
..................................................... 
19 
Study Device Accountability ...................... ......................... ................................... 20 
Study Device Handling and Disposal ............... .............................. ............... .......... 20 
SCREENING ASSESSMENTS ...................... ............. .............. ...................... ....... 20 
Demographics ........ ............. ....................................... ....................... ....... ......... ..... 20 
Medica l History ............ ........................ ....... .............................. ............................. 20 
STUDY ENDPOINTS ................................................
....... ..................................... 20 
Feasibility ...................................... ......................................................................... 
20 
Skin Appearance ....................... ............................... ............ .................. ............... . 20 
Quality of Life ............ ..................................
......... ......... .......... .............................. 20 
Coverage .......................... .............. ............... ..................... ...................................
. 21 
Adverse and Serious Adverse Events ..................... ............ ....... .............................. 21 
Definitions ........ ..................... ........................... ........ ...................... ................. ....... 21 
Adverse Event (AE) ............... ...................................................
.............. .......... ..... 21 
Serious Adverse Event (SAE) .............. ........... .......... ......................... ..................... 21 
Adverse Event Reporting ............. ............. .............................................................. 
21 
Relationship to Study Device .......... ......................................................
.................. 22 
Assessment of Causality ..........................................................................
............... 22 
Recording Adverse Events .................... .................. ............ ...................... .......... .... 22 
Eliciting Adverse Event Reports ..................... ....................... ................................. 22 
Assessment of Intensity ............................ ................. ........... ........................... ....... 22 
Reporting Adverse Events ........... ................. .................................
....................... .. 23 
SAE Reporting Procedures .......................................................
............................. . 23 
Regulatory Reporting Requirements for SAEs .................................... .................... 23 
KeraNetics, LLC. 
CONFIDENTIAL 
Page 9 
DN: PRO-KSCM-CRD-001(01) 

K 
@N 
t· 
Study: KSCM-CRD-001 
era 
e 
ICS 
Version: oo 
Effective Date: 
-fli 01-20l8 .3+ao 1'it CW~3 Mor 1'8 
11.8.2. 
11.8.3. 
11.9. 
12. 
12.1. 
12.2. 
12.3. 
13. 
' 13.1. 
13.2. 
13.3. 
14. 
14.1. 
14.2. 
15. 
15.1. 
15.2. 
15.3. 
16. 
16.1. 
16.2. 
16.3. 
16.4. 
16.5. 
17. 
17.1. 
17.2. 
17.3. 
18. 
Reportin g Safety Information to the IRB .................... ............................................ 23 
Protocol Deviations Due to an Emergency or Adverse Event .................................. 23 
Follow-up of Adverse Events ................................................................................. 24 
STATISTIC S ................................................................ ......................................... 24 
Description of Statistical Methods ................................ .......................................... 24 
Sample Size ............................................................................................................ 24 
Analysis of Patients Withdrawin g Prematurely from the Study ............................... 24 
DIRECT ACCESS TO SOURCE DAT A/DOCUMENTS ....................................... 25 
Study Monitorin g .................................... ......................... ..................................... . 25 
Audits and Inspections ..................... ....................................................................... 25 
Institutional Review Board (IRB) ........................................ ...................... ........ ..... 25 
QUALITY CONTROL AND QUALITY ASSURANCE ....................................... 26 
Regulatory Authority Approval ............................................. ............................. .... 26 
Protocol Modifications .................................... ....................................................... 26 
ETHICS ................................ ....................................... ............................. ............. 26 
Ethics Review ................... · ................................................................................. ..... 26 
Ethical Conduct of the Study ................... ............................................................... 27 
Written Informed Consent .............................. : ....................................................... 27 
DATA HANDLING AND RECORDKEEPING ..................................................... 27 
Case Report Form Completion and Source Documentation .................. ....... ............ 27 
Data Management .................................................................................... ............... 28 
Study Site Close-Out ........... ................................................................................... 28 
Retention of Study Documents and Records ........ ................................................... 28 
Inspection of Records ........................................... .................................................. 29 
INVENTION AND PUBLICATION POLICY ....................................................... 29 
Ownership .......................................................... .................................................... 29 
Confident iality .......................................... ............ ......... ......................................... 29 
Publication ............................ ................................................................................. 29 
LIST OF REFERENCES .............. ; ......................................................................... 30 
KeraNetics, LLC. 
CONFIDENTIAL 
Page 10 
DN: PRO-KSCM-CRD-001(01) 

Effective Date: 
Kerarc>Netics 
Study: KSCM-CRD-001 
Version: 00 
02 91 291-B 3-hW\'\? CW.JJ Mod~ 
3. 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
The following abbreviations and specialist terms are used in this study protocol. 
Table 1: 
Abbreviations and Specialist Terms 
Abbreviation or Specialist Term 
Explanation 
AE 
Adverse Event 
CRF 
Case Repo1t Form 
CRO 
Clinical Research Organization 
cGMP 
Current Good Manufacturing Practice 
FDA 
Food and Drug Administration 
GCP 
Good Clinical Practice 
ICF 
Informed Consent Form 
ICH 
International Conference on Harmonization 
IEC 
Institutional Ethics Committee 
IRB 
Institutional Review Board 
ISO 
International Organization for Standardization 
KRNT 
KeraNetics 
SAE 
Serious Adverse Event 
RD 
Radiation Dermatitis 
SOPs 
Standard Operating Procedures 
SAP 
Statistical Analysis Plan 
USP 
United States Pharmacopoeia 
KeraNetics, LLC. 
CONFIDENTIAL 
Page 11 
DN: PRO-KSCM-CRD-001(01) 

Kera@Netics 
Study: KSCM-CRD-001 
Version: 00 
4. 
INTRODUCTION 
4.1. 
Background 
Effective Date: 
.Ol Ql 2QHr .3-1-.10 l<a" CWo?3Mad8' 
Radiotherapy (RT) is an effective intervention for treating breast cancer. The primary 
mechanism of action of RT is to create enough DNA damage within each tumor cell to prevent 
replication and ultimately induce programmed cell death. This mechanism extends beyond the 
targeted tumor to normal surrounding tissue. This field effect can be visualized by the effect of 
RT on the skin within a treatment portal. Approximately 85% of patients undergoing RT 
experience a moderate-to-severe skin reaction 1• The disturbance of the cutaneous barrier 
function can significantly impact both health-related quality of life and the course of treatment 2• 
If the skin reaction is severe enough, a treatment break may be recommended 3. Managing the 
symptoms associated with skin reactions is important for ensuring completion of RT in a timely 
ma~er and increasing patient self-esteem2• Current skin care recommendations typically 
include the use of non-fragrant, hypo-allergenic moisturizers 2. 
KeraStat Cream is a non-sterile, non-implantable, emulsion-based wound dressing intended to 
act as a protective covering in the management of a variety of minor skin wounds and first and 
second degree (partial thiclmess) burns as well as skin undergoing radiation treatment. KeraStat 
Cream uses human hair-derived keratin proteins and is applied topically to the wound surface to 
absorb exudate, provide a moist environment, and create an environmental barrier supportive of 
healing. 
All ingredients have been used in FDA-approved products. A biological safety profile has been 
established for the keratin protein ingredient in KeraStat Cream. Biocompatibility studies were 
chosen and performed in accordance with ISO 10993-1 :2007, "Biological Evaluation of Medical 
Devices Part 1: Evaluation and Testing ." This testing included a full toxicological risk 
assessment per ISO 10993-17 and 10993-18. Additionally, an FDA-approved hydrogel wound 
dressing containing the keratin proteins, water, and a preservative, called KeraStat Gel, has been 
subjected to a human subject Repeat Insult Patch Test (RIPT) to evaluate the 
irritation/sensitization potential of the product when applied to uncompromised skin. No adverse 
skin reactions were observed in 50 subjects evaluated in the RIPT study, and KeraStat Gel was 
considered a non-primary irritant and non-primary sensitizer to the skin. In addition to 
uncompromised skin, KeraStat Gel was tested in compromised skin to assess human 
sensitization study, the Skin Prick Test (SPT). The results of the SPT demonstrated that there 
was no humoral immune response to keratin and supported pre-clinical testing, which 
determined that the product would not elicit an immune response. 
The current study is considered a nonsignificant risk (NSR) device study according to Food and 
Drug Administration (FDA) guidance and does not require an Investigational Device Exemption 
(IDE) in advance of study conduct. NSR device studies must follow the abbreviated 
requirements presented in 21 CFR 812.2(b) related to label\ng, Institutional Review Board (IRB) 
approval, informed consent, monitoring, records, rep01is, and prohibition against promotion. 
KeraNetics, LLC. 
CONFIDENTIAL 
Page 12 
DN: PRO-KSCM-CRD-001(01) 

Kerarc>Netics 
4.2. 
Rationale 
Study: KSCM-CRD-001 
Version: 00 
Effective Date: 
92 01 20183-1-JOI~ Cw«3t../od~ 
Although well tolerated by most patients, about 30% of patients undergoing RT develop a Grade 
2 or worse early adverse skin reaction (EASR). One study in Taiwan showed 23% of patients 
undergoing chest wall or whole breast irradiation developed moist desquamation based on the 
RTOG scale5• This scale described grade 2 skin toxicity as tender or bright erythema, patchy 
moist desquamation / moderate erythema; Grade 3 skin toxicity was described as confluent moist 
desquamation other than skin fold, pitting edema. Both grade 2 and 3 skin toxicities were 
recorded in the assessment of patients in the Taiwanese study. Another study comparing breast 
IMRT to conventional tangent fields showed a decrease in moist desquamation, as defined by the 
NCI CTC version 2, from 48% to 31 % of patients, suggesting that even with advanced treatment 
techniques, a significant number of patients experience skin toxicity4• 
For this study, we will classify grade 2 or 3 skin toxicity (per the RTOG scale) as an EASR. 
Beyond the discomfort patients may experience, EASRs may result in poor patient outcomes. 
Severe EASRs can require a ''treatment break" which, in some cancers, may result in incomplete 
tumor control and greater chance of local recurrence and lower survival rates. In addition to the 
potential impact on cancer outcomes, EASRs may affect patients' self-esteem due to the 
appearance of their skin and recovery time after treatment. Standard skin regimens often include 
routine application of creams or lotions in an effort to combat the dryness, prevent intenuption of 
the skin's natural barrier (e.g., cracking or flaking), and reduce the appearance of inflammation. 
Patients often begin using these creams/lotions at the start of RT. Providing patients with a 
product that moisturizes and reduces the appearance of inflammation may improve patients' 
satisfaction with their appearance as they progress tlu·ough RT treatment. 
KeraNetics has determined that this study is a non-significant risk study under 21 CPR 812.3(m). 
This device is not intended as an implant. It is not for use supporting or sustaining human life. It 
is not for a use of substantial importance in diagnosing, curing, mitigating , or treating disease or 
otherwise preventing impairment of human health, and it does not otherwise present a serious 
risk to health, safety, or welfare of a subject. Furthermore, KeraStat Cream is classified as a 
wound dressing; wound dressings are classified as nonsignificant risk devices in FDA's 
"Information Sheet Guidance for IRBs, Clinical Investigators, and Sponsors: Significant Risk 
and Nonsignificant Risk Medical Device Studies" published January 2006. 
5. 
TRIAL OBJECTIVES AND PURPOSE 
5.1. 
Objectives 
The primary objectives of the proposed research are to evaluate the feasibility of the use of 
KeraStat Cream and collect data to inform a larger future trial. 
The secondary objectives are to assess the safety and tolerability of KeraStat Cream in subjects 
at risk of radiation dermatitis, to assess the effectiveness of KeraStat Cream and how that 
compares to the current standard of care, and to estimate the amount of KeraStat Cream used per 
patient and coverage on skin. 
KeraNetics, LLC. 
CONFIDENTIAL 
Page 13 
DN: PRO-KSCM-CRD-001(01) 

Kerarc>Netics 
Study: KSCM-CRD-00 I 
Version: 00 
6. 
INVESTIGATIONAL PLAN 
6.1. 
Overall Study Design 
Effective Date: 
-92 81 281~ .3-hW I~ e,w.,;>.3~ad8 
This is a single site, between subject, open-label comparison pilot study to assess the feasibility 
and effectiveness of KeraStat Cream in managing RT skin toxicity. The length of study 
participation for a subject is 8-12 weeks depending on when a subject returns for her final 
follow-up evaluation. The Study Design Schematic is shown below in Figure 1 with the 
Acceptable Study Windows in Table 2. 
Sufficient subjects will be screened such that 24 total subjects will complete the study. Patient 
compliance is expected to be good, so a target recruitment of 26 subjects is desired. 
Once a RT patient is determined to be a candidate for inclusion in this study, they may be 
approached for consent to participate. A total of 26 breast cancer patients scheduled to receive 
RT will be recruited and consented. 
RT will begin 4 to 10 weeks after surgery; the targeted volume will be the ipsilateral breast with 
or without regional lymph nodes. Once the patient has consented to participate in the study, their 
baseline pre-RT assessments can be completed during the radiation treatment-planning process. 
Patients are generally treated with RT Monday through Friday, with weekends and holidays off, 
for approximately 4 to 6 weeks. Patients will be provided with KeraStat Skin Cream for 
application as often as needed but at least twice daily, morning and evening. 
During the course of treatment, the patient sees the radiation oncologist weekly in clinic to 
review the patient's treatment course, monitor the skin's appearance after application of KeraStat 
Skin Cream or standard of care, and answer questions. Breaks in the treatment schedule should 
be avoided whenever possible, but breaks necessitated by RT skin toxicity or for other reasons 
will be recorded. The radiation oncologist will see each patient in follow-up 4-8 weeks after 
completing RT to assess the patient for RT-induced skin and other toxicities that may have 
occurred. 
KeraNetics, LLC. 
CONFIDENTIAL 
Page 14 
DN: PRO-KSCM-CRD-001(01) 

Keratc>Netics 
Study: KSCM-CRD-001 
Version: 00 
Figure 1: 
Study Design Schematic 
Table 2: 
Acceptable Study Windows 
Visit 
Day Visit 
Screening (Visit 1) 
Day 1 
Baseline (Visit 1) 
Day 1 
First evaluation (Visit 2) 
RT Day 8 
Second evaluation (Visit 3) 
RT Day 15 
Third evaluation (Visit 4) 
RT Day 22 
Fourth evaluation (Visit 5) 
RT Day 29 
Fifth evaluation (Visit 6) 
RT Day 36 
Final evaluation (Visit 7) 
Post RT 
Day 30 
6.2. 
Detailed Study Design 
6.2.1. 
Identification of Subjects and Consent 
Effective Date: 
fil •fll-2(HS J-l-~01% cw.;i.311.fo, I~ 
Acceptable Visit Window 
None 
None 
±2 days 
±2 days 
±2 days 
±2 days 
±2 days 
±14 days 
Study personnel will identify potential participants during radiation therapy treatment planning, 
explain the study, and seek to obtain subject consent. Individuals who express an interest will 
review and sign an informed consent form with study staff. 
6.3. 
Number of Subjects 
Twenty-six subjects are anticipated to be required for screening and emollment in order to 
achieve a total of 24 patients participating in this study. Subjects will be randomized to receive 
either standard of care or KeraStat Cream. 
Subjects at screening will be given a sequential subject number starting with 1001, 1002, etc. 
Subject initials will be collected, but not used as an identifier. The subject number will be used 
to identify the subject and all study materials associated with each subject. 
KeraNetics, LLC. 
CONFIDENTIAL 
Page 15 
DN: PRO-KSCM-CRD-001(01) 

Kerarc>Netics 
Study: KSCM-CRD-001 
Version: 00 
6.4. 
Treatment Assignment 
Effective Date: 
.fl2 01-201"83-hWI~ 
C.WJ3 Ma, 18 
All subjects will be randomized to receive one of two test agents: KeraStat Cream or standard of 
care (physician-directed care). 
6.5. 
Study Procedures 
6.5.1. 
Visit 1 
After obtaining consent, ensuring the subject meets study inclusion/exclusion criteria , and 
randomizing the subject , study personnel will photograph the site to be irradiated . Study 
personnel will collect vital signs. Subjects will complete the Dermatology Life Quality Index. 
Study personnel will provide KeraStat Cream to subjects randomized to receive KeraStat Cream. 
Subjects randomized to standard of care will follow the instructions of their radiation oncologist. 
Study personnel will provide subjects with a daily diary form where subjects will note symptoms 
or treatment details of concern. 
6.5.2. 
Weekly Visits through Radiation Therapy 
During regular visits with medical staff, study subjects will also meet with study staff. Study 
staff will obtain photographs of the area of irradiation and collect the daily dairy forms. Study 
personnel will collect vital signs and the physician's assessment of the presence and quality of 
radiation dermatitis using the RTOG scale as well as the physician 's assessment of skin dryness, 
appearance of inflammation, and the skin's natural barrier. Any adverse events will be noted and 
addressed. Subjects will complete the Dermatology Life Quality Index. Study personnel will 
provide KeraStat Cream, as needed, to subjects randomized to receive KeraStat Cream. Subjects 
randomized to standard of care will follow the instructions of their radiation oncologist. Study 
personnel will provide subjects with a daily diary form where subjects will note symptoms or 
treatment details of concern . 
6.5.3. 
Post-Radiation Therapy/Close-Out Visit 
During a final follow up visit with medical staff ( estimated at 4 to 6 weeks post radiation therapy 
termination), or if the subject terminates the study, the study subject will meet with study staff. 
Study staff will obtain photographs of the area of irradiation and collect the daily dairy forms. 
Study personnel will collect vital signs and the physician's assessment of the presence and 
quality of radiation dermatitis using the RTOG scale as well as the physician's assessment of 
skin dryness , appearance of inflammation, and the skin's natural barrier. Any adverse events 
will be noted and addressed. Subjects will complete the Dermatology Life Quality Index. 
6.6. 
Criteria for Study Termination 
The Sponsor reserves the right to temporarily suspend or prematurely discontinue this study at 
any time for reasons including , but not limited to, safety or ethical issues or severe non-
compliance. If the Sponsor dete1mines such action is needed , Sponsor will discuss this with the 
Investigator (including the reasons for taking such action) at that time . When feasible, Sponsor 
will provide advance notification to the Investigator of the impending action prior to it taking 
effect. 
KeraNetics, LLC. 
CONFIDENTIAL 
Page 16 
DN: PRO-KSCM-CRD-001(01) 

Effective Date: 
Kerarc>Netics 
Study: KSCM-CRD-001 
Version: 00 
-0%-61-2618' 
c:3-1-,WI 
8 CWd3 Mar 18 
The Sponsor will promptly inform the Investigator and/or institution conducting the study if the 
study is suspended or terminated for safety reasons and will also inform the regulatory 
authorities of the suspension or termination of the study and the reason(s) for the action. If 
required by applicable regulations, the Investigator or KeraNetics/KeraNetics designee, 
depending on whether the Institutional Review Board (IRB) is a central or local IRB, must 
inform the IRB promptly and provide the reason for the suspension or termination. 
If the study is prematurely discontinued, all study data must be returned to Sponsor. In addition, 
arrangements will be made for all unused study device(s) to be destroyed or returned in 
accordance with the applicable procedures for the study. 
7. 
SELECTION AND WITHDRAWAL OF SUBJECTS 
7.1. 
Subject Inclusion Criteria 
At the Screening Visit (Visit 1), subjects must meet all of the following criteria: 
1. Age 18 to 70 
2. Female 
3. Diagnosis of breast cancer and scheduled to receive 4 to 6 weeks of radiation therapy 
(radiation dose of 42 Gy or more) 
4. Able and willing to sign protocol consent form 
5. Able and willing to document symptoms and treatment details as often as needed, not to 
exceed daily notes 
6. Able and willing to have photographs of the affected area taken regularly 
7.2. 
Subject Exclusion Criteria 
To participate in the study, subjects must not meet any of the following criteria: 
1. Women who are pregnant, lactating/nursing or plan to become pregnant 
2. Previous radiation therapy to the area to be treated with radiation therapy 
3. Receiving palliative radiation therapy 
4. Unhealed or infected surgical sites in the irradiation area 
5. Patients undergoing cytotoxic chemotherapy or concurrent Herceptin as pait of overall 
treatment plan (tamoxifen/aromatase inhibitor allowed) 
6. Use of oral corticosteroids or topical corticosteroids in the irradiation area 
7. Autoimmune disease 
8. Skin disease in target irradiation area 
9. Known allergy to the standard of care or ingredients in KeraStat Cream 
KeraNetics, LLC. 
CONFIDENTIAL 
Page 17 
DN: PRO-KSCM-CRD-001(01) 

Effective Date: 
Kerarc>Netics 
Study: KSCM-CRD-001 
Version: 00 
.02 (:ll 201-B 3- 1-,Wl'if C.W~3Mac I~ 
7.3. 
Subject Completion and Withdrawal 
7.3.1. 
Subject Completion 
A subject will be considered to have completed the study if they complete the entire study 
through the final evaluation (Visit 5 or 6). 
7.3.2. 
Patient Withdrawal (Premature Discontinuation from the Study) 
A documented effort must be made to determine why a subject fails to return for the necessary 
visit or is dropped from the study, and the reason for withdrawal must be recorded in the source 
documents and case report form (CRF). A subject may withdraw or be removed from the study 
for any of the following reasons and will be treated as considered appropriate by the Investigator: 
• 
Subject request (for any reason) 
• 
In the opinion of the Investigator, continuation is not in the best interest of the subject 
• 
A serious or unexpected AE occurs such that continuation in the study is 
inappropriate 
• 
Pregnancy 
• 
RT is stopped 
• 
In the opinion of the Sponsor, continuation is not in the best interest of the subject 
If a subject is prematurely discontinued from participation in the study for any reason, the 
Investigator must follow up on all ongoing adverse events (if any). 
In the event a subject is prematurely discontinued from the study due to an AE, or unexpected 
AE or serious adverse event (SAE) (as defined in Section 11.5.1), the procedures stated in 
Sections 11.3-11.9 must be followed. 
7.3.3. 
Replacement of Patients 
Subjects will not be replaced. 
8. 
TREATMENT OF SUBJECTS 
8.1. 
Description of Subject Device 
KeraStat Cream is a non-sterile, non-implantable, emollient-based wound dressing intended to 
act as a protective covering in the management of a variety of skin conditions. 
KeraNetics, LLC. 
CONFIDENTIAL 
Page 18 
DN: PRO-KSCM-CRD-001(01) 

Effective Date: 
Kera@Netics 
Study: KSCM-CRD-001 
Version: 00 
{)J 91 2ets3-1-ao1'3'c.wa3/.'fod8 
8.2. 
Concomitant Medications and Therapies 
8.2.1. 
Pharmacological Therapy 
I 
Concomitant medications are permitted during this study unless otherwise specified in the 
Exclusion Criteria. 
8.3. 
Randomization 
Patients will be randomized to receive standard of care or KeraStat Cream. 
9. 
STUDY DEVICE MATERIALS AND MANAGEMENT 
9.1. 
Study Device 
KeraStat Cream is a non-sterile, non-implantable, emollient-based wound dressing intended to 
act as a protective covering in the management of a variety of skin conditions. KeraStat Cream 
is designed to be topically applied to the skin surface. When applied, KeraStat Cream covers 
the skin or wound, isolating it from the external environment, absorbing excess exudate and 
facilitating a moist wound environment. 
9.2. 
Study Device Packaging and Labeling 
KeraStat Cream will be provided in multiuse tubes. The study device supplies will be 
maintained at the site under controlled conditions and dispensed by qualified personnel at the 
study site. The study device labels will contain information to meet the applicable regulatory 
requirements. 
9.3. 
Study Device Storage 
The study device must be stored at room temperature (15 to 30°C [59-86°F]). The study device 
must be dispensed or administered according to procedures described herein. Only subjects 
enrolled in the study may receive the study device, in accordance with all applicable regulatory 
requirements. Only authorized site staff may supply the study device. 
9.4. 
Study Device Preparation 
KeraStat Cream final product will be manufactured within applicable current Good 
Manufacturing Practice (cGMP) regulations in accordance with KeraNetics quality system. The 
product will be supplied in the form of a cream and packaged in a multi-use tube as detailed in 
Section 9 .2. 
9.5. 
Administration 
KeraStat Skin Cream has been shown to moisturize the skin and reduce dryness, red~ess, and the 
appearance of inflammation. It should be applied as needed but at least twice daily. 
In this study, patients will apply the cream at least twice-daily during the radiation treatments, 7 
days per week. 
KeraNetics, LLC. 
CONFIDENTIAL 
Page 19 
DN: PRO-KSCM-CRD-001(01) 

Kerarc>Netics 
Study: KSCM-CRD-001 
Version: 00 
9.6. 
Study Device Accountability 
Effective Date: 
-02 91 20Ht3-f-JOl'8' e,w a3fv1o, I~ 
The Investigator is responsible for the study device accountability and record maintenance. 
9.7. 
Study Device Handling and Disposal 
Unused supplies, including the study device, will be disposed of using appropriate 
documentation according to International Conference on Harmonization-Good Clinical Practice 
(ICH-GCP), local requirements, applicable Occupational Safety and Health Administration 
(OSHA) and Environmental Protection Agency (EPA) regulations, and applicable study-specific 
procedures. 
10. 
SCREENING ASSESSMENTS 
The following assessments will be used for screening purposes only and taken after informed 
consent is obtained. 
10.1. 
Demographics 
Basic demographic information will be collected from the subject. This information includes age, 
gender, and race/ethnicity. 
10.2. 
Medical History 
Each subject will provide a brief medical history ( e.g. history of allergic reactions to ensure they 
meet the inclusion/exclusion criteria). Study personnel will review the completed medical 
history form prior to enrolling the subject in the study. Study personnel may ask the subject for 
additional information, as necessary. 
11. 
STUDY ENDPOINTS 
11.1. 
Feasibility 
Feasibility is the compliance rate, defined as the average number of applications per week. 
Participants may track applications in their daily diaries to assist in reporting to their physician at 
the weeldy evaluation visit. 
11.2. 
Skin Appearance 
The appearance of the skin (including dryn~ss, appearance of inflammation, and the natural 
barrier) as observed and recorded by study staff as well as the patient's self-report of satisfaction 
with the appearance of skin during the RT and up to 10 weeks post-RT. 
11.3. 
Quality of Life 
Subject quality of life will be measured using the Dermatology Life Quality Index. Subjects will 
complete the index at each visit. Quality of care will also be assessed qualitatively through 
examination of daily diary notes. 
KeraNetics, LLC. 
CONFIDENTIAL 
Page 20 
DN: PRO-KSCM-CRD-001(01) 

Kerarc>Netics 
11.4. 
Coverage 
Study: KSCM-CRD-001 
Version: 00 
Effective Date: 
(U Ql 26ts 3 -1-Jo l~ Ctt.)~31'-\ar l'i? 
Coverage will be calculated using the compliance rate, the number of tubes of KeraStat Cream 
used, and the estimated surface area (bra size). 
11.5. 
Adverse and Serious Adverse Events 
EASR will also be assessed at four time points from the start of radiotherapy through 4 weeks of 
the post radiotherapy follow-up period. The RTOG scale will be used for classification of 
EASRs related to the skin. The Investigator is responsible for the detection and documentation 
of events meeting the criteria and definition of a non-serious AE or SAE as provided in this 
protocol. During the study, as defined from the time of informed consent until completion of 
study-related procedures, the Investigator or site staff will be responsible for detecting and 
following AEs and SAEs, as detailed in this section of the protocol. Adverse events will be 
reported by the subject ( or, when appropriate, by a caregiver, surrogate, or the subject's legally 
acceptable representative). We will also estimate the incidence of EASR of any grade, and for 
grades 2 and higher. At each time point we will estimate the proportion of women who have 
RT-induced EASR present and also calculate a 95% confidence interval around this estimate. 
11.5.1. 
Definitions 
11.5.1.1. 
Adverse Event (AE) 
An adverse event (AE) is defined as any unfavorable or unintended change in body structure, 
body function, laboratory result ( e.g., chemistry, ECG), or worsening of a pre-existing condition 
associated temporally with the use of the test product, whether or not considered related to the 
test product. 
11.5.1.2. 
Serious Adverse Event (SAE) 
A serious adverse event (SAE) is any untoward medical occurrence that occurs irrespective of 
study treatment assignment, if it satisfies any of these criteria: results in death; is life-threatening; 
requires inpatient hospitalization or prolongs existing hospitalization; results in persistent or 
significant disability or incapacity or substantial disruption of the ability to conduct normal life 
functions; or if the event results in a congenital anomaly or birth defect. All SAEs should be 
reported to the study sponsor within 24 hours of the investigator being aware of the event. 
11.5.2. 
Adverse Event Reporting 
Subjects will be encouraged to spontaneously report any changes in baseline health from the time 
the subject enters the study through study completion. Study staff also will inquire about AEs on 
each visit while the subject is in the research center. All AEs/SAEs will be recorded in the 
source document and the case report form (CRF). 
KeraNetics, LLC. 
CONFIDENTIAL 
Page 21 
DN: PRO-KSCM-CRD-001(01) 

Effective Date: 
Kerarc>Netics 
Study: KSCM-CRD-001 
Version: 00 
~l QI 2Ql83-f-,Wl8CwJ..3~ar 1'8' 
11.6. 
11.6.1. 
Relationship to Study Device 
Assessment of Causality 
The Investigator is obligated to assess the relationship between study device and the occurrence 
of each AE/SAE. The Investigator will use clinical judgment to determine the relationship. 
Alternative causes, such as natural history of the underlying diseases, concomitant therapy, other 
risk factors, and the temporal relationship of the event to the study device will be considered and 
investigated. 
The Investigator will assess causality based on the following definitions: 
• 
Not Related (the AE was more likely explained by causes other than the study 
treatment). 
• 
Related (the study treatment and AE were closely related in time and the AE may be 
explained by exposure to study product: e.g., known adverse effect or recunence on re-
challenge). 
11.7. 
Recording Adverse Events 
When an AE occurs, it is the responsibility of the Investigator to review all documentation (e.g., 
medical progress notes, laboratory, and diagnostics reports) relative to the event. The 
Investigator will then record all relevant information regarding an AE in the CRF. 
The Investigator will attempt to establish a diagnosis of the AE based on signs, symptoms, 
and/or other clinical information. In such cases, the diagnosis should be documented as the 
AE/SAE and not the individual signs/symptoms. 
11.7.1. 
Eliciting Adverse Event Reports 
At each visit, subjects will be asked about AEs by means of a non-leading question, such as 
"how have you been since your last visit?" or "how has the treatment been?" In this way, 
possibly milder, but clinically important, side effects of the study device can be detected. SAEs 
will be reported promptly to KeraNetics as described in the following table once the Investigator 
determines that the event meets the protocol definition of a SAE. 
11.7.2. 
Assessment of Intensity 
The Investigator will make an assessment of intensity for each AE/SAE reported during the 
study. The assessment will be based on the Investigator's clinical judgment. The intensity of 
each AE/SAE recorded in the CRF should be assigned to one of the following categories: 
• 
Mild: An event that is easily tolerated by the subject, causing minimal discomfort 
and not interfering with everyday activities. 
• 
Moderate: An event that is sufficiently discomforting to interfere with normal 
everyday activities. 
• 
Severe: An event that prevents normal everyday activities. 
KeraNetics, LLC. 
CONFIDENTIAL 
DN: PRO-KSCM-CRD-001(01) 
Page 22 

Kerarc>Netics 
Study: KSCM-CRD-001 
Version: 00 
Effective Date: 
.o~ 91-201s 3 , 1-,;io ,~ cwa.3 f..farl&' 
An AE that is assessed as severe should not be confused with a SAE. Severity is a category 
utilized for rating the intensity of an event; both AEs and SAEs can be assessed as severe. 
11.8. 
Reporting Adverse Events 
An unexpected event is one that is not consistent with the subject's past medical history and is 
not evident from previous clinical experience with the test product or reasonably anticipated 
from information known about the test product. Events that are deemed serious, related, and 
unexpected involve special handling and reporting requirements to the IRB. All SAEs will be 
followed until stabilization or improvement. 
11.8.1. 
SAE Reporting Procedures 
Once an Investigator becomes aware that a SAE has occurred in a study subject, she/he will 
report the information as thoroughly as possible with all available details of the event to the 
Sponsors within 24 hours. If the Investigator does not have all information regarding an SAE, 
he/she will not wait to receive additional information before notifying Sponsor of the event. The 
information regarding the event will be updated when additional information is received. The 
Investigator will always provide an assessment of causality at the time of the initial event report 
as described in Section 11.6.1. An email is the preferred method to transmit this information 
regarding a SAE to the project contact for SAE receipt. In rare circumstances and in the absence 
of email equipment, notification by telephone is acceptable, with a copy of the event details sent 
by overnight mail. Initial notification via the telephone does not replace the need for the 
Investigator to complete the SAE report via email within 24 hours. 
11.8.1.1. 
Regulatory Reporting Requirements for SAEs 
Sponsor has a legal responsibility to notify, as appropriate, both the local regulatory authority 
and other regulatory agencies about the safety of a product under clinical investigation. Prompt 
notification of SAEs by the Investigator to the appropriate project contact for SAE receipt is 
essential so that legal obligations and ethical responsibilities towards the safety of other subjects 
are met. 
11.8.2. 
Reporting Safety Information to the IRB 
The Investigator, or responsible person according to local requirements, will comply with the 
applicable local regulatory requirements related to the reporting of SAEs to the Institutional 
Review Board (IRB) / Institutional Ethics Committee (IEC). 
11.8.3. 
Protocol Deviations Due to an Emergency or Adverse Event 
Any subject experiencing an emergency or adverse event requiring immediate medical attention 
will receive appropriate medical management by medical staff at the site and at other clinical 
sites as indicated. These events will be reported to Sponsor as soon as possible. If the medical 
management results in departure from the study protocol, the Sponsor will be responsible for 
granting permission for the subject to continue in the trial if the subject is able to return to study 
protocol adherence in a timely fashion. If the subject cannot return to the study protocol in a 
timely fashion, then the subject will be discontinued from the study. 
KeraNetics, LLC. 
CONFIDENTIAL 
Page 23 
DN: PRO-KSCM-CRD-001(01) 

Kerarc>Netics 
Study: KSCM-CRD-001 
Version: 00 
11.9. 
Follow-up of Adverse Events 
Effective Date: 
02a0l -201S-3-hWl8 Cl,J:l3 Mac I'? 
After the initial AE/SAE report, the Investigator is required to proactively follow each subject 
and provide further information to Sponsor on the subject's condition. All AEs and SAEs 
documented at a previous visit/contact and designated as ongoing, will be reviewed at 
subsequent visits/contacts. 
All AEs and SAEs will be followed until resolution, until the condition stabilizes, until the event 
is otherwise explained, or until the subject is lost to follow-up. Once resolved, the appropriate 
CRF entries will be updated. 
12. 
12.1. 
STATISTICS 
Description of Statistical Methods 
Descriptive statistics will calculated and used to inform additional device development and to 
inform a power calculation for a follow on study, if required. The completion rate will be used 
as a measure of feasibility, with participants with an average of 10 or more applications per week 
being classified as compliant. A 95% confidence interval will be calculated around the estimate 
of compliance. After summary statistics are calculated by group, at-test will be used to compare 
the two treatment groups for the effectiveness outcomes of DLQI score and RTOG score. A 
Fisher's exact test will be used to compare skin appearance issues between the groups. The 
counts for each type of adverse event will be summarized by grade and treatment group. For the 
KeraStat treatment group, the mean coverage will be calculated per square centimeter. 
12.2. 
Sample Size 
Up to 26 subjects will be emolled on this pilot study to assure completion of at least 24 subjects. 
The expected accrual rate is four per month with accrual lasting approximately six months. 
Participants will be randomized equally (n=12 per group) to standard of care or KeraStat Cream. 
With 12 participants in each treatment group expected to complete the study, we will be able to 
calculate a 95% confidence interval around the compliance rate in each group with a maximum 
margin of error of O .283. Comparisons between groups for effectiveness (RTOG scale and 
DLQI score) will have 80 percent power to detect a difference of 1.2 standard deviations. 
12.3. 
Analysis of Patients Withdrawing Prematurely from the Study 
All information for withdrawing subjects will be included in the analyses. Subjects who 
withdraw prematurely from the study will have any completed assessments included in the data 
summary. 
KeraNetics, LLC . 
CONFIDENTIAL 
Page 24 
DN: PRO-KSCM-CRD-001(01) 

Effective Date: 
Kerarc>Netics 
Study: KSCM-CRD-001 
Version: 00 
{)2 Ql 201-8 3-1-:101~ C.W~3Mad? 
13. 
13.1. 
DIRECT ACCESS TO SOURCE DATA/DOCUMENTS 
Study Monitoring 
In accordance with applicable regulations, ICH-GCP and procedures covering the study, a 
monitor will contact the site prior to the subject emollment to review the protocol and data 
collection procedures with site staff. In addition, the monitor will periodically contact the site, 
including conducting on-site visits at an appropriate frequency to ensure data quality and to 
ensure the safety and rights of subjects are being protected. 
The Investigator agrees to allow the monitor direct access to all relevant documents and to 
allocate his/her time and the time of his/her staff to the monitor to discuss findings and any 
relevant issues. 
At study closure, monitors will also conduct all activities described in Section 16.3. 
13.2. 
Audits and Inspections 
To ensure compliance with Good Clinical Practices and all applicable regulatory requirements, 
quality assurance audits may occur during the study or after the study is complete. Authorized 
representatives of KeraNetics, a regulatory authority, or an IRB may visit the site to perform 
audits or inspections to examine all study-related activities and documents to determine whether 
these activities were conducted, and data were recorded, analyzed, and accurately reported 
according to the protocol, ICH-GCP, and any applicable regulatory requirements. 
If an audit or inspection occurs, the Investigator and institution agree to allow the 
auditor/inspector direct access to all relevant documents and to allocate his/her time and the time 
of his/her staff to the auditor/inspector to discuss findings and any relevant issues. The 
Investigator should contact the Sponsor immediately if contacted by a regulatory agency about 
an inspection. 
13.3. 
Institutional Review Board (IRB) 
This study will be conducted in full compliance with the Institutional Review Board (IRB) 
regulations in 21 CFR 56 and applicable local regulatory guidance. 
IRB approval for the investigation must be obtained before the study is initiated. Initial IRB 
approval, and all materials approved by the IRB for this study including the patient consent form, 
and recruitment materials must be maintained by the Investigator and made available for 
inspection. 
The current study is considered a nonsignificant risk (NSR) device study according to FDA 
guidance and does not require an Investigational Device Exemption (IDE) in advance of study 
conduct. NSR device studies must follow the abbreviated requirements presented in 21 CFR 
812.2(b) related to labeling, Institutional Review Board (IRB) approval, informed consent, 
monitoring, records, reports, and prohibition against promotion. 
KeraNetics, LLC. 
CONFIDENTIAL 
Page 25 
DN: PRO-KSCM-CRD-001(01) 

Kerarc>Netics 
Study: KSCM-CRD-001 
Version: 00 
Effective Date: 
9~ QI 291& 3+JD\'kw~3 Mo( If 
14. 
QUALITY CONTROL AND QUALITY ASSURANCE 
To ensure compliance with Good Clinical Practices and all applicable regulatory requirements, 
Sponsor ( or representative of Sponsor) may conduct a quality assurance audit. Please see 
Section 13.2 and 16.5 for more details regarding the audit process at any time during the conduct 
of the study or after study completion. 
14.1. 
Regulatory Authority Approval 
Not applicable. This is an NSR device. 
14.2. 
Protocol Modifications 
The initial protocol as well as all protocol amendments must be signed and dated by the 
Investigator and approved by the IRB prior to implementation of the original protocol and any 
amendment. The Principal Investigator must submit all protocol modifications to the IRB, as 
applicable for specific Investigators, or applicable local regulatory authority. 
Departures from the protocol will be determined as allowable on a case-by-case basis or in event 
of an emergency involving subject safety. The Investigator or other physician in attendance 
must contact Sponsor as soon as possible to discuss the circumstances of the emergency. 
Sponsor, in concurrence with the Investigator, will decide whether the subject should continue to 
participate in the study. All protocol deviations and the reason for such deviations must be noted 
on the source document and in the CRF and reported to the IRB as appropriate. 
15. 
15.1. 
ETHICS 
Ethics Review 
The Investigator is responsible for ensuring that this protocol, the site's informed consent form 
(ICF), and any other information that will be presented to potential subjects (e.g., advertisements 
or information that suppo1is or supplements the informed consent) are reviewed and approved by 
the appropriate IRB. The Investigator agrees to allow the IRB direct access to all relevant 
documents. The IRB must be constituted in accordance with all applicable regulatory 
requirements. Sponsor will provide the Investigator with relevant document(s)/data that are 
needed for IRB review and approval of the study. The IRB must approve the study and ICF 
before study device(s) and other study material can be supplied to the site. 
If the protocol, the ICF, or any other information that the IRB has approved for presentation to 
potential subjects is amended during the study, the Investigator is responsible for ensuring the 
IRB reviews and approves, where applicable, these amended documents. The Investigator must 
follow all applicable regulatory requirements pertaining to the use of an amended ICF including 
obtaining IRB approval of the amended form before new subjects consent to take part in the 
study using this version of the form. Copies of the IRB approval of the amended I CF/other 
information and the approved amended !CF/other information must be maintained in the 
regulatory files at the site. 
KeraNetics, LLC. 
CONFIDENTIAL 
Page 26 
DN: PRO-KSCM-CRD-001(01) 

Effective Date: 
Keralc>Netics 
Study: KSCM-CRD-001 
Version: 00 
OJ Ql 2918 3- hW l'ir e.tv.;)3 Marl~ 
15.2. 
Ethical Conduct of the Study 
This study will be conducted in accordance with ICH-GCP guidelines and all applicable 
regulatory requirements, including, where applicable, the Declaration of Helsinki. 
15.3. 
Written Informed Consent 
This study will be conducted in full compliance with the informed consent regulations in 21 CFR 
50. The consent form must be reviewed and approved by the Sponsor prior to submission to the 
IRB. The consent form must be approved by the IRB prior to initiation of the study. 
No Investigator may involve a human being as a subject in research unless the Investigator has 
obtained the legally effective informed consent of the subject or the subject's legally authorized 
representative. An Investigator may seek such consent only under circumstances that provide the 
prospective subject or the representative sufficient opportunity to consider whether to participate 
and that minimize the possibility of coercion or undue influence. The information given to the 
subject or the representative must be in a language understandable to the subject or the 
representative. No informed consent, whether oral or written, may include any exculpatory 
language through which the subject or the representative is made to waive or appear to waive any 
of the subject's legal rights, or releases or appears to release the Investigator, the institution, the 
Sponsor, or its agents from liability for negligence. 
An !RB-approved consent form should inform each prospective subject or the legally authorized 
representative of each prospective subject of the purpose and the nature of the study, its possible 
hazards and benefits, and the subject's right to withdraw from the study at any time without 
prejudice to further treatment. Exemptions to the requirement for informed consent in the United 
States are described in 21 CFR 50.23. 
The Investigator(s) at each center will ensure that the patient is given full and adequate oral and 
written information about the nature, purpose, possible risk and benefit of the study. Patients 
must also be notified that they are free to discontinue from the study at any time. The patient 
should be given the opportunity to ask questions and allowed time to consider the information 
provided. 
The Investigator is responsible for obtaining written consent (signed and dated ICF) from 
potential subjects prior to performing any tests or assessments required by the protocol. A copy 
of the signed consent document will be given to the subject and the original retained by the 
Investigator. 
16. 
16.1. 
DATA HANDLING AND RECORDKEEPING 
Case Report Form Completion and Source Documentation 
The Investigator is required to prepare and maintain adequate and accurate case histories 
designed to record all observations and other data pertinent to the study for each study 
participant. Subject data are collected by the Investigator or designee using source documents 
that are transferred to a CRF, defined in collaboration with Sponsor. Subject data necessary for 
analysis and reporting will be entered onto the source documents and then provided to the 
KeraNetics, LLC. 
CONFIDENTIAL 
Page 27 
DN: PRO-KSCM-CRD-001(01) 

Effective Date: 
Kerarc>Netics 
Study: KSCM-CRD-001 
Version: 00 
..{12 tH 20Hl 3+.;iol&- CW.Q3Mar I<? 
Sponsor as an electronic compilation of raw data from source documents via secure file 
exchange. 
All information entered in the CRFs must be consistent with the subject's source documentation 
(i.e., medical records). The Investigator is responsible for the accuracy of the data transcribed 
from all source documentation . CRF entries should be made within a reasonable timeframe from 
the time of a subject's visit. Instances of missing or uninterpretable data will be brought to the 
attention of the Investigator and/or Sponsor for resolution. 
16.2. 
Data Management 
Clinical data management will be performed in accordance with applicable study standards and 
data cleaning procedures. All data will be collected and stored on-site in REDCap. Database lock 
will occur when data management quality control procedures are completed. 
16.3. 
Study Site Close-Out 
Upon completion of the study, the monitor may conduct the following activities in conjunction 
with the Investigator or site staff, as appropriate: 
1. Resolve data queries. 
2. Accountability, reconciliation, and return of unused study device(s). 
3. Review of final site study records for completeness. 
4. Return all study-specific equipment to Sponsor. 
16.4. 
Retention of Study Documents and Records 
Following closure of the study, the Investigator must maintain all site study records in a safe and 
secure location . All study-related data will be retained by and are the sole property of Sponsor. 
The Investigator will retain a copy of all source documents and CRF data (i.e., DVD-ROM 
containing pdf files of data) for the subjects enrolled at the site. The records must be maintained 
to allow easy and timely retrieval, when needed (e.g., audit or inspection). Where permitted by 
local laws/regulations or institutional policy, some or all of these records can be maintained in a 
format other than hard copy (e.g., microfiche, scanned, electronic); however, caution needs to be 
exercised before such action is taken. The Investigator must assure that all reproductions are 
legible and are a true and accurate copy of the original and meet ·accessibility and retrieval 
standards, including re-generating a hard copy, if required. Furthermore , the Investigator must 
ensure there is an acceptable back-up of these reproductions and that an acceptable quality 
control process exists for making these reproductions. 
Sponsor will inform the Investigator of the time period for retaining these records to comply with 
all applicable regulatory requirements. The minimum retention time will meet the strictest 
standard applicable to that site for the study, as dictated by any institutional requirements or local 
laws or regulations, or Sponsor standards/procedures; otherwise, the retention period will default 
to 5 years . 
KeraNetics, LLC. 
CONFIDENTIAL 
Page 28 
DN: PRO-KSCM-CRD-001(01) 

Kerarc>Netics 
Study: KSCM-CRD-001 
Version: 00 
Effective Date: 
-02 91 29l-83-I-J01%' c.w..;>3 ~a, I'd' 
The Investigator must notify Sponsor of any changes in the archival arrangements, including, but 
not limited to, the following: archival at an off-site facility, transfer of ownership of the records 
in the event the Investigator leaves the site. 
16.5. 
Inspection of Records 
Sponsor ( or a representative of Sponsor) will be allowed to conduct site visits to the investigation 
facilities for the purpose of monitoring any aspect of the study. The Investigator agrees to allow 
the monitor to inspect the storage area, study device stocks, study material accountability 
records, subject charts and study source documents, and other records relative to study conduct. 
17. 
INVENTION AND PUBLICATION POLICY 
In the event of a conflict between the provisions of this section and a written contract regarding 
the conduct of the study between Sponsor ( or a contract research organization) and the site, the 
Investigator or any person assisting Investigator with the Study, the terms of that contract shall 
control. 
17.1. 
Ownership 
All information provided by or on behalf of Sponsor and all data and information generated by 
the site, the Investigator or any person assisting Investigator with the study as part of or in 
connection with the study (other than a subject's medical records), is the sole and exclusive 
property of Sponsor. All rights , title, and interests in and to any inventions, discoveries or know-
how made, conceived, learned or first reduced to practice by the site, Investigator or any person 
assisting Investigator with the study during the course of, in relation to, or as a result of the study 
(and any intellectual property rights related thereto) are the sole and exclusive property of the 
Sponsor, and are hereby assigned to Sponsor. 
17.2. 
Confidentiality 
All information provided by Sponsor and all data and information generated by the site as part of 
or in relation to the study (other than a subject's medical records) will be kept confidential by the 
Investigator, the site, and any person assisting Investigator with the study. This information and 
data shall not be used by the site, Investigator, or any person assisting Investigator with the study 
for any purpose other than conducting the study. These restrictions do not apply to: 1) 
information which becomes publicly available through no fault of the site, Investigator or any 
person assisting Investigator with the study; 2) information which it is necessary to disclose in 
confidence to an IRB solely for the evaluation of the study; 3) information which it is necessary 
to disclose in order to provide appropriate medical care to a study subject; or 4) study results 
which are permitted to be published as described in the next section. 
17.3. 
Publication 
Investigator may publish the results of the study only for noncommercial, educational or 
academic purposes provided that prior to making the publication, or otherwise disclosing the 
study results, Investigator provides Sponsor with a copy of the proposed publication and allows 
KeraNetics, LLC. 
CONFIDENTIAL 
Page 29 
DN: PRO-KSCM-CRD-001(01) 

Effective Date: 
Keratc>Netics 
Study: KSCM-CRD-001 
Version: 00 
02 IH 2018 3~1-JOl'if r1,i~3 J\lar J'(i' 
Sponsor a reasonable period to review. Proposed publications shall not include Sponsor's 
confidential information ( other than the study results) or personal data with respect to any subject 
(such as name or initials) and if Sponsor identifies any confidential information in a proposed 
publication, it shall be removed. 
At the request of Sponsor, the submission, publication or other disclosure of a proposed 
publication will be delayed a sufficient time to allow KeraNetics to seek patent or similar 
protection of any inventions, know-how or other intellectual or industrial property rights 
contained in such proposed publication . 
18. 
LIST OF REFERENCES 
1. 
Salvo N, Barnes E, van Draanen J, et al. Prophylaxis and management of acute radiation-
induced skin reactions: a systematic review of the literature. Curr Oneal. 2010;17( 4):94-
112. 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid =2913836&tool=pmcentrez&re 
ndertype=abstract. Accessed July 23, 2014. 
2. 
Bensadoun R-J, Humbert P, Krutmah J, et al. Daily baseline skin care in the prevention , 
treatment , and supportive care of skin toxicity in oncology patients : recommendations 
from a multinational expert panel. Cancer Manag Res. 2013;5:401 -408. 
doi: 10.2147/CMAR.S52256. 
3. 
Glover D, Harmer V. Radiotherapy-induced skin reactions: assessment and management. 
Br J Nurs. 23(4):S28 , S30-5. http://www.ncbi.nlm.nih.gov/pubmed/24619051. Accessed 
July 23, 2014. 
4. 
Pignol J-P, Olivotto I, Rakovitch E, et al. A Multicenter Randomized Trial of Breast 
Intensity-Modulated Radiation Therapy to Reduce Acute Radiation Dermatitis . J Clin 
Oneal. 2008;26(13):2085-2092. doi: 10.1200/JC0.2007 .15.2488. 
5. 
Chen M-F, Chen W-C, Lai C-H, Hung C-H, Liu K-C, Cheng Y-H. Predictive factors of 
radiation-induced skin toxicity in breast cancer patients. BMC Cancer. 2010;10(1):508. 
doi:10.l 186/1471-2407-10-508. 
KeraNetics, LLC. 
CONFIDENTIAL 
Page 30 
DN: PRO-KSCM-CRD-001(01)